The FDA on 29 November 2012 approved Cometriq (cabozantinib),formerly XL 184, from Exelixis Inc., to treat medullary Thyroid Cancer that...
Swedish Orphan Biovitrum AB's and Exelixis, Inc. announced that the European Commission has approved Cometriq (cabozantinib) for the treatment of...
Exelixis has announced positive overall survival (OS) results from METEOR, the phase III pivotal trial comparing Cometriq (cabozantinib) to everolimus...
Exelixis, Inc. has announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion...
Exelixis has announced top-line results from the final analysis of COMET-1, the Phase III pivotal trial of Cometriq (cabozantinib) in...
Exelixis, Inc.announced that the FDA has approved Cabometyx (cabozantinib) (formerly Cometriq) tablets for the treatment of patients with advanced renal...
Exelixis has completed the submission of its rolling New Drug Application (NDA) with the FDA for Cometriq (cabozantinib) as a...
Exelixis has submitted a Marketing Authorization Application (MAA) for Cometriq (cabozantinib) as a treatment for patients with advanced renal cell...
Exelixis announced positive results from a post-hoc analysis of METEOR, the phase III pivotal trial comparing Cometriq (cabozantinib) to everolimus...
The National Institute for Health and Care Excellence (NICE) announced in draft guidance that it was not recommending Sanof's Caprelsa...